Shandong Zezheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Zezheng Pharmaceutical") was founded by Mr. Ho Dunwei from Johnson & Johnson in 2016. It is a research and development enterprise focusing on the consistency evaluation of the quality and efficacy of generic drugs and the development of generic drugs. In 2017, Zhengzheng Pharmaceutical Subsidiary Shanghai Yiwen Biotechnology Co., Ltd. was established, focusing on the research and development of high-end preparations and oral liquid preparations for children.
Since its establishment in 2016, under the guidance of talent and science and technology policy, it has successively won ten top new and cutting-edge enterprises in Zibo High-tech Zone in 2017, awarded scientific and technological innovation awards in Zibo High-tech Zone for three consecutive years from 2016 to 2018, and Mr. He Dunwei, the company, was recognized as the leader of Taishan Industry in Shandong Province (science and technology entrepreneurship category) in 2018, and foreign experts introduced by the company were selected as "foreign specialists" in Shandong Province. At the same time, the company has been recognized as one of the first high-tech enterprises to pass the certification in the first half of 2018 in Shandong Province.
The company has a group of strong, experienced and enthusiastic R&D personnel and management backbone. Most of the managers are from Johnson & Johnson, GlaxoSmithKline, Pfizer, TEVA, SGS and other multinational enterprises. Currently, there are five technical departments: preparation department, analysis department, quality department, clinical department and registration department. The R&D personnel account for 85% of the total number.
The company has built 1500 square meters of laboratories in Zibo which meet the FDA standards. It makes full use of Shandong Province generic consistency evaluation platform and establishes a platform covering the technical capabilities of reference preparation analysis, prescription process development, pharmaceutical evaluation, pre-BE and BE test. High-end pharmaceutical research and development center was established in Shanghai in early 2017, focusing on high-end pharmaceutical development and overseas declaration. It has 1000 square laboratories in Shanghai. Phase I has opened 450 square meters. In 2017, it successfully established hot melt extrusion and slow-release pellet technology platform. The company has introduced a technical team of generic drug development from India and other countries, focusing on the development of oral sustained and controlled release preparations.
Since its establishment, the company has reached cooperation or strategic cooperation with more than 20 well-known pharmaceutical companies at home and abroad, such as Johnson & Johnson, and established cooperative relations with Insignis, Pharma Synergy and Aizant in India. In May 2017, the company became the first pharmaceutical enterprise to establish strategic cooperation with provincial (Shandong) Food and Drug Inspection Research Institute. In 2018, it successfully passed the quality audits of Johnson & Johnson and Fesenyuskabi.
Zezheng Pharmaceutical has always adhered to the core values of "Mu Cong Sheng Ze Zheng". With the vision of making the Chinese people can afford the good medicines of international standards, Zezheng Pharmaceutical is committed to establishing scientific, compliance and innovative drug research and development institutions.